Browse RAB11A

Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor Recycling endosome membrane Lipid-anchor Cleavage furrow Cytoplasmic vesicle, phagosome Note=Translocates with RAB11FIP2 from the vesicles of the endocytic recycling compartment (ERC) to the plasma membrane (PubMed:11994279). Localizes to the cleavage furrow (PubMed:15601896). Colocalizes with PARD3, PRKCI, EXOC5, OCLN, PODXL and RAB8A in apical membrane initiation sites (AMIS) during the generation of apical surface and lumenogenesis (PubMed:20890297). Recruited to phagosomes containing S.aureus or M.tuberculosis (PubMed:21255211).
Domain PF00071 Ras family
Function

The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. That Rab regulates endocytic recycling. Acts as a major regulator of membrane delivery during cytokinesis. Together with MYO5B and RAB8A participates in epithelial cell polarization. Together with RAB3IP, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis. Together with MYO5B participates in CFTR trafficking to the plasma membrane and TF (Transferrin) recycling in nonpolarized cells. Required in a complex with MYO5B and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Participates in the sorting and basolateral transport of CDH1 from the Golgi apparatus to the plasma membrane. Regulates the recycling of FCGRT (receptor of Fc region of monomeric Ig G) to basolateral membranes. May also play a role in melanosome transport and release from melanocytes.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000226 microtubule cytoskeleton organization
GO:0000819 sister chromatid segregation
GO:0000910 cytokinesis
GO:0001558 regulation of cell growth
GO:0001667 ameboidal-type cell migration
GO:0003014 renal system process
GO:0003091 renal water homeostasis
GO:0006887 exocytosis
GO:0007009 plasma membrane organization
GO:0007032 endosome organization
GO:0007033 vacuole organization
GO:0007034 vacuolar transport
GO:0007051 spindle organization
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0007080 mitotic metaphase plate congression
GO:0007346 regulation of mitotic cell cycle
GO:0007409 axonogenesis
GO:0008361 regulation of cell size
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010796 regulation of multivesicular body size
GO:0010971 positive regulation of G2/M transition of mitotic cell cycle
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016049 cell growth
GO:0016197 endosomal transport
GO:0022604 regulation of cell morphogenesis
GO:0030104 water homeostasis
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030516 regulation of axon extension
GO:0030953 astral microtubule organization
GO:0031122 cytoplasmic microtubule organization
GO:0031346 positive regulation of cell projection organization
GO:0032400 melanosome localization
GO:0032401 establishment of melanosome localization
GO:0032402 melanosome transport
GO:0032535 regulation of cellular component size
GO:0033059 cellular pigmentation
GO:0036257 multivesicular body organization
GO:0036258 multivesicular body assembly
GO:0040017 positive regulation of locomotion
GO:0043473 pigmentation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0045666 positive regulation of neuron differentiation
GO:0045773 positive regulation of axon extension
GO:0045787 positive regulation of cell cycle
GO:0045927 positive regulation of growth
GO:0045931 positive regulation of mitotic cell cycle
GO:0048167 regulation of synaptic plasticity
GO:0048168 regulation of neuronal synaptic plasticity
GO:0048169 regulation of long-term neuronal synaptic plasticity
GO:0048227 plasma membrane to endosome transport
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048871 multicellular organismal homeostasis
GO:0050000 chromosome localization
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0050804 modulation of synaptic transmission
GO:0050878 regulation of body fluid levels
GO:0050891 multicellular organismal water homeostasis
GO:0051036 regulation of endosome size
GO:0051225 spindle assembly
GO:0051272 positive regulation of cellular component movement
GO:0051303 establishment of chromosome localization
GO:0051310 metaphase plate congression
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051875 pigment granule localization
GO:0051904 pigment granule transport
GO:0051905 establishment of pigment granule localization
GO:0051962 positive regulation of nervous system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060627 regulation of vesicle-mediated transport
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090066 regulation of anatomical structure size
GO:0090068 positive regulation of cell cycle process
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090150 establishment of protein localization to membrane
GO:0090307 mitotic spindle assembly
GO:0098813 nuclear chromosome segregation
GO:1901987 regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902751 positive regulation of cell cycle G2/M phase transition
GO:1902850 microtubule cytoskeleton organization involved in mitosis
GO:1990138 neuron projection extension
GO:1990182 exosomal secretion
GO:1990778 protein localization to cell periphery
GO:2000147 positive regulation of cell motility
Molecular Function GO:0000149 SNARE binding
GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0017022 myosin binding
GO:0019001 guanyl nucleotide binding
GO:0019905 syntaxin binding
GO:0031489 myosin V binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component GO:0000922 spindle pole
GO:0005770 late endosome
GO:0005771 multivesicular body
GO:0005802 trans-Golgi network
GO:0005813 centrosome
GO:0005819 spindle
GO:0005828 kinetochore microtubule
GO:0005874 microtubule
GO:0005876 spindle microtubule
GO:0010008 endosome membrane
GO:0030133 transport vesicle
GO:0030139 endocytic vesicle
GO:0030424 axon
GO:0030659 cytoplasmic vesicle membrane
GO:0031984 organelle subcompartment
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0044440 endosomal part
GO:0045335 phagocytic vesicle
GO:0055037 recycling endosome
GO:0055038 recycling endosome membrane
GO:0097610 cell surface furrow
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
hsa04961 Endocrine and other factor-regulated calcium reabsorption
hsa04962 Vasopressin-regulated water reabsorption
hsa04972 Pancreatic secretion
Reactome R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-445717: Aquaporin-mediated transport
R-HSA-5620920: Cargo trafficking to the periciliary membrane
R-HSA-5617833: Cilium Assembly
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-597592: Post-translational protein modification
R-HSA-8873719: RAB geranylgeranylation
R-HSA-8854214: TBC/RABGAPs
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
R-HSA-5653656: Vesicle-mediated transport
R-HSA-5620916: VxPx cargo-targeting to cilium
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAB11A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAB11A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAB11A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5850.0235
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6410.792
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.550.745
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0040.991
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3820.822
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4880.811
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1460.747
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0020.999
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2960.897
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0590.98
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4210.906
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1830.0332
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAB11A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAB11A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAB11A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAB11A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAB11A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAB11A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAB11A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAB11A
NameRAB11A, member RAS oncogene family
Aliases YL8; RAB 11A, member oncogene family; rab-11; Ras-related protein Rab-11A
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAB11A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting RAB11A.
ID Name Drug Type Targets #Targets
DB018645'-Guanosine-Diphosphate-MonothiophosphateSmall MoleculeARF6, RAB11A, TGM33
DB04315Guanosine-5'-DiphosphateSmall MoleculeADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......36